NO326659B1 - Fremgangsmate ved bestemmelse av transformerende effekt hos et mulig transformerende middel ved bestemmelse av apoptoseinduserende aktivitet - Google Patents
Fremgangsmate ved bestemmelse av transformerende effekt hos et mulig transformerende middel ved bestemmelse av apoptoseinduserende aktivitet Download PDFInfo
- Publication number
- NO326659B1 NO326659B1 NO20000736A NO20000736A NO326659B1 NO 326659 B1 NO326659 B1 NO 326659B1 NO 20000736 A NO20000736 A NO 20000736A NO 20000736 A NO20000736 A NO 20000736A NO 326659 B1 NO326659 B1 NO 326659B1
- Authority
- NO
- Norway
- Prior art keywords
- apoptin
- cells
- apoptosis
- cancer
- normal
- Prior art date
Links
- 230000000694 effects Effects 0.000 title claims abstract description 28
- 230000001939 inductive effect Effects 0.000 title claims abstract description 16
- 230000001131 transforming effect Effects 0.000 title claims description 27
- 238000000034 method Methods 0.000 title claims description 20
- 230000006907 apoptotic process Effects 0.000 title abstract description 82
- 230000008569 process Effects 0.000 title description 3
- 101710094856 Apoptin Proteins 0.000 claims abstract description 211
- 210000004027 cell Anatomy 0.000 claims abstract description 171
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 19
- 239000013612 plasmid Substances 0.000 claims description 46
- 230000001640 apoptogenic effect Effects 0.000 claims description 28
- 230000006882 induction of apoptosis Effects 0.000 claims description 23
- 210000001840 diploid cell Anatomy 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 7
- 239000013603 viral vector Substances 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 60
- 201000011510 cancer Diseases 0.000 abstract description 53
- 238000011282 treatment Methods 0.000 abstract description 12
- 241000725585 Chicken anemia virus Species 0.000 abstract description 5
- 239000003183 carcinogenic agent Substances 0.000 abstract description 3
- 230000003449 preventive effect Effects 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 230000004913 activation Effects 0.000 abstract description 2
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 108010067390 Viral Proteins Proteins 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 35
- 210000004940 nucleus Anatomy 0.000 description 27
- 210000002950 fibroblast Anatomy 0.000 description 25
- 101710128836 Large T antigen Proteins 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 22
- 230000009261 transgenic effect Effects 0.000 description 18
- 101710185500 Small t antigen Proteins 0.000 description 17
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 16
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 16
- 238000003556 assay Methods 0.000 description 16
- 238000001890 transfection Methods 0.000 description 15
- 239000012634 fragment Substances 0.000 description 14
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 238000010166 immunofluorescence Methods 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 12
- 241000283984 Rodentia Species 0.000 description 11
- 210000005260 human cell Anatomy 0.000 description 11
- 108010044052 Desmin Proteins 0.000 description 10
- 102100036912 Desmin Human genes 0.000 description 10
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- 210000000805 cytoplasm Anatomy 0.000 description 9
- 239000012894 fetal calf serum Substances 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 210000005045 desmin Anatomy 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 8
- 230000006698 induction Effects 0.000 description 7
- 230000004807 localization Effects 0.000 description 7
- 210000001161 mammalian embryo Anatomy 0.000 description 7
- 241001529936 Murinae Species 0.000 description 6
- 108700020796 Oncogene Proteins 0.000 description 6
- 102000043276 Oncogene Human genes 0.000 description 6
- 230000004186 co-expression Effects 0.000 description 6
- 230000000381 tumorigenic effect Effects 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000012623 DNA damaging agent Substances 0.000 description 4
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 4
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 230000004987 nonapoptotic effect Effects 0.000 description 4
- 230000007420 reactivation Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000003146 transient transfection Methods 0.000 description 4
- 231100000588 tumorigenic Toxicity 0.000 description 4
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 3
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 3
- 101100289792 Squirrel monkey polyomavirus large T gene Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000011319 anticancer therapy Methods 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000013020 embryo development Effects 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000001626 skin fibroblast Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 230000030570 cellular localization Effects 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 208000035255 cutaneous malignant susceptibility to 2 melanoma Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000025600 response to UV Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- IUYLLUJNDLENRE-UHFFFAOYSA-N 2-phenylindole-2,4-diamine Chemical compound C1=C2C(N)=CC=CC2=NC1(N)C1=CC=CC=C1 IUYLLUJNDLENRE-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102100037152 BAG family molecular chaperone regulator 1 Human genes 0.000 description 1
- 101710089792 BAG family molecular chaperone regulator 1 Proteins 0.000 description 1
- 208000005692 Bloom Syndrome Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101900018054 Chicken anemia virus Apoptin Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 238000011771 FVB mouse Methods 0.000 description 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 1
- 101000928044 Homo sapiens Desmin Proteins 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 201000011062 Li-Fraumeni syndrome Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 101150050863 T gene Proteins 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 101150036700 VP3 gene Proteins 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000005955 cellular translocation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007711 cytoplasmic localization Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 108010027775 interleukin-1beta-converting enzyme inhibitor Proteins 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 101150072261 large T gene Proteins 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000016833 positive regulation of signal transduction Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
- Measurement Of Current Or Voltage (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97202501 | 1997-08-12 | ||
| PCT/NL1998/000457 WO1999008108A1 (en) | 1997-08-12 | 1998-08-11 | Determining the transforming capability of agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20000736D0 NO20000736D0 (no) | 2000-02-14 |
| NO20000736L NO20000736L (no) | 2000-04-11 |
| NO326659B1 true NO326659B1 (no) | 2009-01-26 |
Family
ID=8228640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20000736A NO326659B1 (no) | 1997-08-12 | 2000-02-14 | Fremgangsmate ved bestemmelse av transformerende effekt hos et mulig transformerende middel ved bestemmelse av apoptoseinduserende aktivitet |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6528247B1 (cs) |
| EP (1) | EP1004021B1 (cs) |
| JP (1) | JP4287588B2 (cs) |
| KR (1) | KR20010022812A (cs) |
| AT (1) | ATE283478T1 (cs) |
| AU (1) | AU756587B2 (cs) |
| BR (1) | BR9811163A (cs) |
| CA (1) | CA2301401C (cs) |
| CZ (1) | CZ299874B6 (cs) |
| DE (1) | DE69827805T2 (cs) |
| NO (1) | NO326659B1 (cs) |
| NZ (1) | NZ502800A (cs) |
| PL (1) | PL196605B1 (cs) |
| RU (1) | RU2214598C2 (cs) |
| SK (1) | SK286235B6 (cs) |
| WO (1) | WO1999008108A1 (cs) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW514581B (en) * | 1999-09-02 | 2002-12-21 | Ciba Sc Holding Ag | A method of protecting wood against light-induced degradation by treatment with an impregnation which penetrates the surface of the wood |
| EA005933B1 (ru) * | 1999-09-02 | 2005-08-25 | Леадд Б.В. | Апоптин-ассоциированный белок |
| WO2001042461A2 (en) | 1999-12-10 | 2001-06-14 | Leadd B.V. | Apoptin-associating protein |
| EP1199363A1 (en) | 2000-10-20 | 2002-04-24 | Leadd B.V. | Phosphorylation modifications of apoptin |
| PT1377667E (pt) * | 2001-03-30 | 2009-03-13 | Leadd Bv | Proteínas de fusão para o tratamento específico de cancro e doenças auto-imunitárias |
| SE0302312D0 (sv) * | 2002-10-04 | 2003-08-27 | Forskarpatent I Syd Ab | Peptide-based passive immunization therapy for treatment of atherosclerosis |
| AU2003904086A0 (en) | 2003-08-04 | 2003-08-21 | Cochlear Limited | Implant battery short circuit protection |
| DK2658872T3 (da) | 2010-12-27 | 2020-10-12 | Apo T B V | Polypeptid, der binder aberrerende celler og inducerer apoptose |
| WO2013048243A1 (en) | 2011-09-29 | 2013-04-04 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
| JP2015504895A (ja) | 2012-01-13 | 2015-02-16 | エーピーオー‐ティー ビー．ヴイ． | 毒性部分を備える異常細胞拘束性免疫グロブリン |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL9002008A (nl) | 1990-09-12 | 1992-04-01 | Stichting Centr Diergeneeskund | Recombinant dna en rna en daarvan afgeleide produkten. |
| KR0162670B1 (ko) * | 1991-01-15 | 1999-05-01 | 마르쿠 잘카넨 | 세포의 악성 전형을 나타내기 위한 조직 및 체액과 같은 생물학적 물질에서의 신데칸 내용물의 검출 |
| EP0878546A1 (en) | 1997-04-15 | 1998-11-18 | Leadd B.V. | A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin |
| CZ82692A3 (en) * | 1992-03-19 | 1994-02-16 | Prirodovedecka Fakulta Uk | Method of testing cyctotoxicity and genotoxicity of chemicals |
| ATE241808T1 (de) | 1995-06-07 | 2003-06-15 | Leadd Bv | Verwendungen von apoptin |
| JPH1015250A (ja) | 1996-06-28 | 1998-01-20 | Sega Enterp Ltd | ゲーム装置 |
| EP0921192A1 (en) * | 1997-12-03 | 1999-06-09 | Leadd B.V. | Molecules interacting with apoptin |
| EP0927757A1 (en) * | 1997-12-03 | 1999-07-07 | Leadd B.V. | Methods and means for inducing apoptosis by interfering with Bip-like proteins |
-
1998
- 1998-08-11 WO PCT/NL1998/000457 patent/WO1999008108A1/en not_active Application Discontinuation
- 1998-08-11 CA CA002301401A patent/CA2301401C/en not_active Expired - Fee Related
- 1998-08-11 RU RU2000106046/14A patent/RU2214598C2/ru not_active IP Right Cessation
- 1998-08-11 US US09/485,551 patent/US6528247B1/en not_active Expired - Fee Related
- 1998-08-11 JP JP2000506525A patent/JP4287588B2/ja not_active Expired - Fee Related
- 1998-08-11 NZ NZ502800A patent/NZ502800A/xx unknown
- 1998-08-11 CZ CZ20000479A patent/CZ299874B6/cs not_active IP Right Cessation
- 1998-08-11 KR KR1020007001413A patent/KR20010022812A/ko not_active Application Discontinuation
- 1998-08-11 PL PL338683A patent/PL196605B1/pl not_active IP Right Cessation
- 1998-08-11 AT AT98939016T patent/ATE283478T1/de not_active IP Right Cessation
- 1998-08-11 SK SK190-2000A patent/SK286235B6/sk not_active IP Right Cessation
- 1998-08-11 EP EP98939016A patent/EP1004021B1/en not_active Expired - Lifetime
- 1998-08-11 BR BR9811163-9A patent/BR9811163A/pt not_active Application Discontinuation
- 1998-08-11 AU AU87529/98A patent/AU756587B2/en not_active Ceased
- 1998-08-11 DE DE69827805T patent/DE69827805T2/de not_active Expired - Lifetime
-
2000
- 2000-02-14 NO NO20000736A patent/NO326659B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001512829A (ja) | 2001-08-28 |
| CZ299874B6 (cs) | 2008-12-17 |
| ATE283478T1 (de) | 2004-12-15 |
| DE69827805D1 (de) | 2004-12-30 |
| SK286235B6 (sk) | 2008-06-06 |
| NZ502800A (en) | 2002-10-25 |
| US6528247B1 (en) | 2003-03-04 |
| DE69827805T2 (de) | 2005-12-15 |
| PL338683A1 (en) | 2000-11-20 |
| WO1999008108A1 (en) | 1999-02-18 |
| AU8752998A (en) | 1999-03-01 |
| SK1902000A3 (en) | 2000-11-07 |
| EP1004021B1 (en) | 2004-11-24 |
| AU756587B2 (en) | 2003-01-16 |
| NO20000736L (no) | 2000-04-11 |
| JP4287588B2 (ja) | 2009-07-01 |
| CZ2000479A3 (cs) | 2000-06-14 |
| BR9811163A (pt) | 2000-07-25 |
| RU2214598C2 (ru) | 2003-10-20 |
| KR20010022812A (ko) | 2001-03-26 |
| EP1004021A1 (en) | 2000-05-31 |
| CA2301401C (en) | 2008-10-21 |
| CA2301401A1 (en) | 1999-02-18 |
| PL196605B1 (pl) | 2008-01-31 |
| NO20000736D0 (no) | 2000-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shinoura et al. | Protein and messenger RNA expression of connexin43 in astrocytomas: implications in brain tumor gene therapy | |
| Coates et al. | Mammalian prohibitin proteins respond to mitochondrial stress and decrease during cellular senescence | |
| Robanus-Maandag et al. | p107 is a suppressor of retinoblastoma development in pRb-deficient mice | |
| Zheng et al. | Disruption of E-cadherin by matrix metalloproteinase directly mediates epithelial-mesenchymal transition downstream of transforming growth factor-β1 in renal tubular epithelial cells | |
| Hufbauer et al. | Human papillomavirus mediated inhibition of DNA damage sensing and repair drives skin carcinogenesis | |
| Feddersen et al. | In vivo viability of postmitotic Purkinje neurons requires pRb family member function | |
| Singh et al. | The BH3 only Bcl-2 family member BNIP3 regulates cellular proliferation | |
| NO326659B1 (no) | Fremgangsmate ved bestemmelse av transformerende effekt hos et mulig transformerende middel ved bestemmelse av apoptoseinduserende aktivitet | |
| Bulloj et al. | Semaphorin4D-PlexinB1 signaling attenuates photoreceptor outer segment phagocytosis by reducing Rac1 activity of RPE cells | |
| JP2017527265A (ja) | 神経芽細胞腫の研究のための動物モデル | |
| Hsu et al. | Dysfunctional spermatogenesis in transgenic mice overexpressing bHLH-Zip transcription factor, Spz1 | |
| Sung et al. | Mutations in non-muscle myosin 2A disrupt the actomyosin cytoskeleton in Sertoli cells and cause male infertility | |
| Heinrich et al. | ATF3 regulates the expression of AChE during stress | |
| Hariri et al. | Degenerated hair follicle cells and partial loss of sebaceous and eccrine glands in a familial case of axenfeld-rieger syndrome: An emerging role for the FOXC1/NFATC1 genetic axis | |
| Pinkert et al. | Tumorigenesis in transgenic mice by a nuclear transport-defective SV40 large T-antigen gene | |
| MXPA00001410A (en) | Determining the transforming capability of agents | |
| Regeling et al. | Mice defective in p53 nuclear localization signal 1 exhibit exencephaly | |
| EP1304371A1 (en) | Cds1 GENE-KNOCKOUT CELLS AND MOUSE AND UTILIZATION THEREOF | |
| Bodey et al. | Molecular Markers of Brain Tumor Cells: Implications for Diagnosis, Prognosis and Anti-neoplastic Biological Therapy | |
| US20110047631A1 (en) | Heat shock protein deficiencies as model systems for brain pathology and cancer | |
| Sun | Characterization of Rb1 function in the absence of normal E2F binding | |
| Hayward et al. | Rescue and isolation of Rb-deficient prostate epithelium by tissue recombination | |
| Leung | Immortalization of human ovarian surface epithelium with a temperature sensitive immortalization agent | |
| Ostrowski | Elucidating the Role of UbE2K in the Post-Translational Regulation of the Tumor Suppressor PTEN | |
| Yoon et al. | C/EBP |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |